{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:16:24Z","timestamp":1787030184114,"version":"build-2736575974"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council (NHMRC) Project","doi-asserted-by":"publisher","award":["APP1043519"],"award-info":[{"award-number":["APP1043519"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council (NHMRC) Project","doi-asserted-by":"publisher","award":["APP1153493"],"award-info":[{"award-number":["APP1153493"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHMRC Centre of Research Excellence in Tuberculosis Control","award":["APP1043519"],"award-info":[{"award-number":["APP1043519"]}]},{"name":"NHMRC Centre of Research Excellence in Tuberculosis Control","award":["APP1153493"],"award-info":[{"award-number":["APP1153493"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>There is an urgent need for an effective TB vaccine capable of controlling both acute and chronic Mycobacterium tuberculosis infection in populations with diverse genetic backgrounds. In this study, we characterised the immunogenicity and protective efficacy of a novel protein-in-adjuvant subunit vaccine. The protein component is a fusion protein of three different M. tuberculosis antigens, which we termed CysVac5: CysD, a major component of the M. tuberculosis sulfate activation pathway that is highly expressed during the chronic stage of M. tuberculosis infection, is fused with two major secreted mycobacterial antigens, Ag85B and MPT83. Vaccination of C57BL\/6 mice with CysVac5, formulated in a monophosphoryl lipid A (MPLA) and dimethyldioctadecylammonium (DDA) adjuvant combination, resulted in the potent generation of polyfunctional CD4+ T cells secreting multiple cytokines, including IFN-\u03b3, IL-2, TNF and IL-17, against each of the three components of the fusion protein. Furthermore, vaccination with CysVac5-MPLA\/DDA conferred significant protection against infection in mouse lungs, which was greater than that afforded by BCG at extended time points post-challenge. The generation of antigen-specific and protective immunity was also observed in CysVac5 vaccinated BALB\/c mice, indicating the vaccine could display efficacy across multiple genetic backgrounds. These results indicate that the CysVac5 vaccine has broad immunogenicity, is effective in controlling both acute and chronic phases of M. tuberculosis infection in mice, and warrants further investigation to assess its potential to control pulmonary TB.<\/jats:p>","DOI":"10.3390\/vaccines12090997","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T09:39:32Z","timestamp":1725010772000},"page":"997","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and Protective Efficacy of a Multi-Antigen Mycobacterium tuberculosis Subunit Vaccine in Mice"],"prefix":"10.3390","volume":"12","author":[{"given":"Annuurun","family":"Nisa","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney Infectious Diseases Institute (Sydney ID), Camperdown, NSW 2050, Australia"},{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pinto","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney Infectious Diseases Institute (Sydney ID), Camperdown, NSW 2050, Australia"},{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6721-9646","authenticated-orcid":false,"given":"Warwick J.","family":"Britton","sequence":"additional","affiliation":[{"name":"Centre for Infection and Immunity, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Department of Clinical Immunology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Triccas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney Infectious Diseases Institute (Sydney ID), Camperdown, NSW 2050, Australia"},{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Centre for Infection and Immunity, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Counoupas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney Infectious Diseases Institute (Sydney ID), Camperdown, NSW 2050, Australia"},{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Centre for Infection and Immunity, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024, May 07). Global Tuberculosis Report 2022. Available online: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2022."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bagcchi, S. (2023). WHO\u2019s global tuberculosis report 2022. Lancet Microbe, 4.","DOI":"10.1016\/S2666-5247(22)00359-7"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kaufmann, S.H.E. (2023). Vaccine development against tuberculosis before and after COVID-19. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1273938"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kaech, S.M., Wherry, E.J., and Ahmed, R. (2002). Vaccines: Effector and memory T-cell differentiation: Implications for vaccine development. Nat. Rev. Immunol., 2.","DOI":"10.1038\/nri778"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1517\/14712598.7.10.1539","article-title":"Tuberculosis subunit vaccines: From basic science to clinical testing","volume":"7","author":"Doherty","year":"2007","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bellini, C., and Horv\u00e1ti, K. (2020). Recent advances in the development of protein-and peptide-based subunit vaccines against tuberculosis. Cells, 9.","DOI":"10.3390\/cells9122673"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41577-019-0174-z","article-title":"Moving tuberculosis vaccines from theory to practice","volume":"19","author":"Andersen","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final Analysis of a Trial of M72\/AS01(E) Vaccine to Prevent Tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dijkman, K., Lindenstrom, T., Rosenkrands, I., Soe, R., Woodworth, J.S., Lindestam Arlehamn, C.S., and Mortensen, R. (2023). A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG. NPJ Vaccines, 8.","DOI":"10.1038\/s41541-023-00666-2"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Woodworth, J.S., Clemmensen, H.S., Battey, H., Dijkman, K., Lindenstrom, T., Laureano, R.S., Taplitz, R., Morgan, J., Aagaard, C., and Rosenkrands, I. (2021). A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guerin. Nat. Commun., 12.","DOI":"10.1038\/s41467-021-26934-0"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1099\/mic.0.26894-0","article-title":"The Mycobacterium tuberculosis cysD and cysNC genes form a stress-induced operon that encodes a tri-functional sulfate-activating complex","volume":"150","author":"Pinto","year":"2004","journal-title":"Microbiology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/infdis\/jis751","article-title":"Host Cell\u2014Induced Components of the Sulfate Assimilation Pathway Are Major Protective Antigens of Mycobacterium tuberculosis","volume":"207","author":"Pinto","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Counoupas, C., Pinto, R., Nagalingam, G., Hill-Cawthorne, G.A., Feng, C.G., Britton, W.J., and Triccas, J.A. (2016). Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice. NPJ Vaccines, 1.","DOI":"10.1038\/npjvaccines.2016.12"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Counoupas, C., Ferrell, K.C., Ashhurst, A., Bhattacharyya, N.D., Nagalingam, G., Stewart, E.L., Feng, C.G., Petrovsky, N., Britton, W.J., and Triccas, J.A. (2020). Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. NPJ Vaccines, 5.","DOI":"10.1038\/s41541-020-00255-7"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.vaccine.2018.03.066","article-title":"Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis","volume":"36","author":"Counoupas","year":"2018","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1002\/1873-3468.12273","article-title":"Mycobacterium tuberculosis lipoproteins in virulence and immunity\u2013fighting with a double-edged sword","volume":"590","author":"Becker","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kao, F.F., Mahmuda, S., Pinto, R., Triccas, J.A., West, N.P., and Britton, W.J. (2012). The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034991"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.1700030","article-title":"Mycobacterium tuberculosis Lipoprotein MPT83 Induces Apoptosis of Infected Macrophages by Activating the TLR2\/p38\/COX-2 Signaling Pathway","volume":"198","author":"Wang","year":"2017","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nusbaum, R.J., Calderon, V.E., Huante, M.B., Sutjita, P., Vijayakumar, S., Lancaster, K.L., Hunter, R.L., Actor, J.K., Cirillo, J.D., and Aronson, J. (2016). Pulmonary tuberculosis in humanized mice infected with HIV-1. Sci. Rep., 6.","DOI":"10.1038\/srep21522"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: Implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(14)70033-5","article-title":"Progress in tuberculosis vaccine development and host-directed therapies\u2014A state of the art review","volume":"2","author":"Kaufmann","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Martin, C., Aguilo, N., Marinova, D., and Gonzalo-Asensio, J. (2020). Update on TB vaccine pipeline. Appl. Sci., 10.","DOI":"10.3390\/app10072632"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Counoupas, C., Pinto, R., Nagalingam, G., Britton, W.J., Petrovsky, N., and Triccas, J.A. (2017). Delta inulin-based adjuvants promote the generation of polyfunctional CD4(+) T cell responses and protection against Mycobacterium tuberculosis infection. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-09119-y"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ogongo, P., Tezera, L.B., Ardain, A., Nhamoyebonde, S., Ramsuran, D., Singh, A., Ng\u2019oepe, A., Karim, F., Naidoo, T., and Khan, K. (2021). Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung. J. Clin. Investig., 131.","DOI":"10.1172\/JCI142014"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, W., Deng, G., Zhang, G., Yu, Z., Yang, F., Chen, J., Cai, Y., Werz, O., and Chen, X. (2020). Genetic polymorphism rs8193036 of IL17A is associated with increased susceptibility to pulmonary tuberculosis in Chinese Han population. Cytokine, 127.","DOI":"10.1016\/j.cyto.2019.154956"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1016\/j.vaccine.2016.09.002","article-title":"Polyfunctional CD4 T-cells correlate with in vitro mycobacterial growth inhibition following Mycobacterium bovis BCG-vaccination of infants","volume":"34","author":"Smith","year":"2016","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lewinsohn, D.A., Lewinsohn, D.M., and Scriba, T.J. (2017). Polyfunctional CD4(+) T Cells As Targets for Tuberculosis Vaccination. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01262"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Carpenter, S.M., and Lu, L.L. (2022). Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.830482"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","article-title":"Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6","volume":"69","author":"Andersen","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hossain, M.S., Azad, A.K., Chowdhury, P.A., and Wakayama, M. (2017). Computational Identification and Characterization of a Promiscuous T-Cell Epitope on the Extracellular Protein 85B of Mycobacterium spp. for Peptide-Based Subunit Vaccine Design. Biomed. Res. Int., 2017.","DOI":"10.1155\/2017\/4826030"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mahanty, S., Prigent, A., and Garraud, O. (2015). Immunogenicity of infectious pathogens and vaccine antigens. BMC Immunol., 16.","DOI":"10.1186\/s12865-015-0095-y"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/IAI.00985-10","article-title":"Joint effects of host genetic background and mycobacterial pathogen on susceptibility to infection","volume":"79","author":"Correa","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Abel, L., El-Baghdadi, J., Bousfiha, A.A., Casanova, J.-L., and Schurr, E. (2014). Human genetics of tuberculosis: A long and winding road. Phil. Trans. R. Soc. B, 369.","DOI":"10.1098\/rstb.2013.0428"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Creissen, E., Izzo, L., Dawson, C., and Izzo, A.A. (2021). Guinea Pig Model of Mycobacterium tuberculosis Infection. Curr. Protoc., 1.","DOI":"10.1002\/cpz1.312"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/997\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:45:46Z","timestamp":1760111146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["vaccines12090997"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12090997","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}